Evidence map›Paper›PMID 42693171›Full record

Reviewnpj drug discovery2026

Closing the recapitulation gap in obesity-conditioned TNBC drug development.

Karim I Budhwani, Erica M Stringer-Reasor, Anna G Sorace, Donald J Buchsbaum, Chelsea L Crawford

Abstract readReview
In one paragraph

Review in npj drug discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Karim I BudhwaniCerFlux, Birmingham, AL, USA. IronMan@CerFlux.com.ORCID http://orcid.org/0000-0001-8823-1695
Erica M Stringer-ReasorUniversity of Alabama at Birmingham, Birmingham, AL, USA.
Anna G SoraceUniversity of Alabama at Birmingham, Birmingham, AL, USA.
Donald J BuchsbaumCerFlux, Birmingham, AL, USA.
Chelsea L CrawfordCerFlux, Birmingham, AL, USA.

Funding

Development of personalized ex vivo predictive technology for rapidly matching patient tumors with chemotherapy regimens before treatment.R43CA254493 · NCI · CERFLUX, INC. · PI BUDHWANI, KARIM I · 2020 to 2021
$301k
National Science Foundation TI-2321805NCI NIH HHS 1R43CA254493-01NCI NIH HHS R43 CA254493
6 · The paper itself

Abstract

Preclinical cancer models do not always recapitulate clinical treatment response, as therapeutic response may depend on tissue context the model does not reproduce. Using obesity-conditioned triple-negative breast cancer as a lens, we argue that the tumor microenvironment acts through dual gates-controlling access and altering behavior-and propose the recapitulation gap as a measurable model-to-patient divergence to guide fit-for-purpose drug development.

Identifiers

PMID42693171
PMCPMC13542197

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.